ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Exploring the Impact of Anti-PD-1 and Anti-PD-L1 Agents in Merkel Cell Carcinoma

Suzanne L. Topalian, MD
Published Online:8:43 PM, Wed August 16, 2017

Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery, Johns Hopkins Medicine, discusses the impact of anti-PD-1 and anti-PD-L1 agents in the treatment of merkel cell carcinoma.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.